Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients

Effect of hyperinsulinemia

Giuseppe Cella, Roberto Vettor, Alessandra Sbarai, Edoardo Rossi, Ernesto Rampin, Cinzia Macor, Michele Mussap, Mario Plebani, Guido Luzzatto, Antonio Girolami

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

It has been suggested that the extrinsic coagulation system plays a crucial role in the initiation of blood coagulation in atherosclerotic disease and that TFPI, the inhibitor of the factor VIIa/tissue factor complex, bound to the endothelial cells, could prevent in vivo blood clotting. Because obesity has a role in the pathogenesis of atherosclerotic cardiovascular disease, we measured TFPI antigen plasma levels (ng/mL) by ELISA at baseline and 5 minutes after an IV bolus of 20 IU/kg body weight of unfractionated commercial mucous heparin in 12 obese patients with a mean body mass index (BMI) of 41.4 ± 1.4 kg/m2 and 14 normal-weight control subjects (BMI 23.1 ± 1.3 kg/m2). All subjects were submitted to an OGTT. The obese patients displayed a normal glucose tolerance. However, they had a different glucose-induced hyperinsulinemia (14.9 ± 2.0 versus 7.8 ± 0.8 mU/L, p <0.01). Total serum cholesterol did not differ between controls and obese patients, whereas plasma triglycerides were higher in the latter group. Basal TFPI antigen plasma levels were similar in obese and controls (83.8 ± 5.0 versus 77.7 ± 3.5 ng/mL, p = N.S.). In contrast, after heparin a significantly lower rise in TFPI antigen plasma levels was observed in obese patients (319.3 ± 37.9 ng/mL) as compared to controls (511.2 ± 43.4 ng/mL) (p <0.003). Moreover, a significant inverse correlation was found between the heparin-stimulated TFPI antigen plasma levels and both BMI and basal plasma insulin concentrations. Thus, the link between insulin level and endothelial cell-associated TFPI could at least partially explain why obese patients are more prone to develop cardiovascular disorders.

Original languageEnglish
Pages (from-to)129-134
Number of pages6
JournalSeminars in Thrombosis and Hemostasis
Volume23
Issue number2
Publication statusPublished - 1997

Fingerprint

Hyperinsulinism
Endothelial Cells
Antigens
Heparin
Body Mass Index
Blood Coagulation
Insulin
Glucose
Factor VIIa
Thromboplastin
Glucose Tolerance Test
lipoprotein-associated coagulation inhibitor
Triglycerides
Cardiovascular Diseases
Obesity
Enzyme-Linked Immunosorbent Assay
Cholesterol
Body Weight
Weights and Measures
Serum

Keywords

  • Heparin
  • Hyperinsulinemia
  • Lipids
  • Obesity
  • TFPI

ASJC Scopus subject areas

  • Hematology

Cite this

Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients : Effect of hyperinsulinemia. / Cella, Giuseppe; Vettor, Roberto; Sbarai, Alessandra; Rossi, Edoardo; Rampin, Ernesto; Macor, Cinzia; Mussap, Michele; Plebani, Mario; Luzzatto, Guido; Girolami, Antonio.

In: Seminars in Thrombosis and Hemostasis, Vol. 23, No. 2, 1997, p. 129-134.

Research output: Contribution to journalArticle

Cella, G, Vettor, R, Sbarai, A, Rossi, E, Rampin, E, Macor, C, Mussap, M, Plebani, M, Luzzatto, G & Girolami, A 1997, 'Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients: Effect of hyperinsulinemia', Seminars in Thrombosis and Hemostasis, vol. 23, no. 2, pp. 129-134.
Cella, Giuseppe ; Vettor, Roberto ; Sbarai, Alessandra ; Rossi, Edoardo ; Rampin, Ernesto ; Macor, Cinzia ; Mussap, Michele ; Plebani, Mario ; Luzzatto, Guido ; Girolami, Antonio. / Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients : Effect of hyperinsulinemia. In: Seminars in Thrombosis and Hemostasis. 1997 ; Vol. 23, No. 2. pp. 129-134.
@article{18ab48aecfc6408a832a0f80457b233b,
title = "Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients: Effect of hyperinsulinemia",
abstract = "It has been suggested that the extrinsic coagulation system plays a crucial role in the initiation of blood coagulation in atherosclerotic disease and that TFPI, the inhibitor of the factor VIIa/tissue factor complex, bound to the endothelial cells, could prevent in vivo blood clotting. Because obesity has a role in the pathogenesis of atherosclerotic cardiovascular disease, we measured TFPI antigen plasma levels (ng/mL) by ELISA at baseline and 5 minutes after an IV bolus of 20 IU/kg body weight of unfractionated commercial mucous heparin in 12 obese patients with a mean body mass index (BMI) of 41.4 ± 1.4 kg/m2 and 14 normal-weight control subjects (BMI 23.1 ± 1.3 kg/m2). All subjects were submitted to an OGTT. The obese patients displayed a normal glucose tolerance. However, they had a different glucose-induced hyperinsulinemia (14.9 ± 2.0 versus 7.8 ± 0.8 mU/L, p <0.01). Total serum cholesterol did not differ between controls and obese patients, whereas plasma triglycerides were higher in the latter group. Basal TFPI antigen plasma levels were similar in obese and controls (83.8 ± 5.0 versus 77.7 ± 3.5 ng/mL, p = N.S.). In contrast, after heparin a significantly lower rise in TFPI antigen plasma levels was observed in obese patients (319.3 ± 37.9 ng/mL) as compared to controls (511.2 ± 43.4 ng/mL) (p <0.003). Moreover, a significant inverse correlation was found between the heparin-stimulated TFPI antigen plasma levels and both BMI and basal plasma insulin concentrations. Thus, the link between insulin level and endothelial cell-associated TFPI could at least partially explain why obese patients are more prone to develop cardiovascular disorders.",
keywords = "Heparin, Hyperinsulinemia, Lipids, Obesity, TFPI",
author = "Giuseppe Cella and Roberto Vettor and Alessandra Sbarai and Edoardo Rossi and Ernesto Rampin and Cinzia Macor and Michele Mussap and Mario Plebani and Guido Luzzatto and Antonio Girolami",
year = "1997",
language = "English",
volume = "23",
pages = "129--134",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients

T2 - Effect of hyperinsulinemia

AU - Cella, Giuseppe

AU - Vettor, Roberto

AU - Sbarai, Alessandra

AU - Rossi, Edoardo

AU - Rampin, Ernesto

AU - Macor, Cinzia

AU - Mussap, Michele

AU - Plebani, Mario

AU - Luzzatto, Guido

AU - Girolami, Antonio

PY - 1997

Y1 - 1997

N2 - It has been suggested that the extrinsic coagulation system plays a crucial role in the initiation of blood coagulation in atherosclerotic disease and that TFPI, the inhibitor of the factor VIIa/tissue factor complex, bound to the endothelial cells, could prevent in vivo blood clotting. Because obesity has a role in the pathogenesis of atherosclerotic cardiovascular disease, we measured TFPI antigen plasma levels (ng/mL) by ELISA at baseline and 5 minutes after an IV bolus of 20 IU/kg body weight of unfractionated commercial mucous heparin in 12 obese patients with a mean body mass index (BMI) of 41.4 ± 1.4 kg/m2 and 14 normal-weight control subjects (BMI 23.1 ± 1.3 kg/m2). All subjects were submitted to an OGTT. The obese patients displayed a normal glucose tolerance. However, they had a different glucose-induced hyperinsulinemia (14.9 ± 2.0 versus 7.8 ± 0.8 mU/L, p <0.01). Total serum cholesterol did not differ between controls and obese patients, whereas plasma triglycerides were higher in the latter group. Basal TFPI antigen plasma levels were similar in obese and controls (83.8 ± 5.0 versus 77.7 ± 3.5 ng/mL, p = N.S.). In contrast, after heparin a significantly lower rise in TFPI antigen plasma levels was observed in obese patients (319.3 ± 37.9 ng/mL) as compared to controls (511.2 ± 43.4 ng/mL) (p <0.003). Moreover, a significant inverse correlation was found between the heparin-stimulated TFPI antigen plasma levels and both BMI and basal plasma insulin concentrations. Thus, the link between insulin level and endothelial cell-associated TFPI could at least partially explain why obese patients are more prone to develop cardiovascular disorders.

AB - It has been suggested that the extrinsic coagulation system plays a crucial role in the initiation of blood coagulation in atherosclerotic disease and that TFPI, the inhibitor of the factor VIIa/tissue factor complex, bound to the endothelial cells, could prevent in vivo blood clotting. Because obesity has a role in the pathogenesis of atherosclerotic cardiovascular disease, we measured TFPI antigen plasma levels (ng/mL) by ELISA at baseline and 5 minutes after an IV bolus of 20 IU/kg body weight of unfractionated commercial mucous heparin in 12 obese patients with a mean body mass index (BMI) of 41.4 ± 1.4 kg/m2 and 14 normal-weight control subjects (BMI 23.1 ± 1.3 kg/m2). All subjects were submitted to an OGTT. The obese patients displayed a normal glucose tolerance. However, they had a different glucose-induced hyperinsulinemia (14.9 ± 2.0 versus 7.8 ± 0.8 mU/L, p <0.01). Total serum cholesterol did not differ between controls and obese patients, whereas plasma triglycerides were higher in the latter group. Basal TFPI antigen plasma levels were similar in obese and controls (83.8 ± 5.0 versus 77.7 ± 3.5 ng/mL, p = N.S.). In contrast, after heparin a significantly lower rise in TFPI antigen plasma levels was observed in obese patients (319.3 ± 37.9 ng/mL) as compared to controls (511.2 ± 43.4 ng/mL) (p <0.003). Moreover, a significant inverse correlation was found between the heparin-stimulated TFPI antigen plasma levels and both BMI and basal plasma insulin concentrations. Thus, the link between insulin level and endothelial cell-associated TFPI could at least partially explain why obese patients are more prone to develop cardiovascular disorders.

KW - Heparin

KW - Hyperinsulinemia

KW - Lipids

KW - Obesity

KW - TFPI

UR - http://www.scopus.com/inward/record.url?scp=8544237727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544237727&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 129

EP - 134

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 2

ER -